5 recruiting, 2 active not recruiting, 2 completed, 1 suspended. 7 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 4, Active not recruiting 2, Suspended 1 |
| Phase 1 | 6 | Completed 2, Recruiting 2, Suspended 1, Withdrawn 1 |
Follow Recurrent Grade 3b Follicular Lymphoma: new trials by email Literature Review of Recurrent Grade 3b Follicular Lymphoma trials Research Report on Recurrent Grade 3b Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T Odronextamab, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of Washington | 27 | 2025-09-04 | 2026-08-28 |
| Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Recruiting | Yazeed Sawalha | 38 | 2025-04-02 | 2026-08-25 |
| Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Mayo Clinic | 41 | 2025-04-02 | 2026-10-20 |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Recruiting | AIDS Malignancy Consortium | 20 | 2025-02-13 | 2026-07-10 |
| Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 36 | 2024-01-02 | 2026-10-08 |
| Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Carboplatin - Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Active not recruiting | David Bond, MD | 37 | 2023-06-29 | 2026-07-20 |
| TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Ontorpacept - Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Mayo Clinic | 10 | 2023-04-19 | 2026-04-22 |
| NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Completed | Fred Hutchinson Cancer Center | 27 | 2022-12-08 | 2026-09-21 |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma Blinatumomab, Lenalidomide - Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2016-11-15 | 2025-11-26 |
Lymphoma, Large B-Cell, Diffuse (11) · Lymphoma, B-Cell (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2) · Burkitt Lymphoma (1) · HIV Infections (1)
Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoma (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Lymphoma, Non-Hodgkin (9) · Lymphoma, B-Cell (8) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Infections (2) · Leukemia (2)
Biopsy (8) · Magnetic Resonance Spectroscopy (8) · Specimen Handling (6) · Leukapheresis (3) · Spinal Puncture (3) · Cyclophosphamide (2) · Immunotherapy, Adoptive (2) · Lenalidomide (2) · Phantoms, Imaging (2) · X-Rays (2) · fludarabine (2) · CPG-oligonucleotide (1) · CT-P10 (1) · Carboplatin (1) · Disulfides (1)
City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · Mayo Clinic (2) · AIDS Malignancy Consortium (1) · David Bond, MD (1) · National Cancer Institute (NCI) (1) · University of Washington (1) · Yazeed Sawalha (1)
United States (10)
Alexandre Hirayama (1) · Alexandre V. Hirayama, MD (1) · Ariela Noy (1) · Claire Tiger, MD, PhD (1) · David A Bond, MD (1) · Joseph M Tuscano (1) · Lihua E Budde (1) · Mengyang Di, MD, PhD (1) · Stephen M. Ansell, MD, PhD (1) · Swetha Kambhampati (1) · Yazeed Sawalha (1)
P30CA033572 (2), P50CA107399 (1), UM1CA121947 (1), UM1CA186644 (1), UM1CA186717 (1)